GlassScriptPhysician profile
Arina Tutunik
NPI 1497983001
$374.65
in general payments reported to CMS, 2019-2025
10 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $55.18 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $103.36 | 2025 | |
| Exeltis, USA INC. | $86.91 | 2019-2020 | |
| Allergan, INC. | $48.21 | 2019-2020 | |
| Abbvie INC. | $30.88 | 2019 | |
| Aspira Women'S Health INC | $20.00 | 2020 | |
| Shire North American Group INC | $18.91 | 2019 | |
| Duchesnay USA Incorporated | $17.81 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.14 | 2019 | |
| Therapeuticsmd, INC. | $16.67 | 2019 | |
| Tactile Systems Technology INC | $14.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arina Tutunik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.